Management of Worsening Kidney Function in Dialysis Patients with Heart Failure

Immediate Assessment Priorities

• The American Journal of Kidney Diseases recommends assessing for persistent congestion using clinical examination and point-of-care ultrasound, including inferior vena cava assessment and Venous Excess Ultrasound (VEXUS) score, to evaluate volume status in dialysis patients with heart failure 1.
• Congestion remains the primary driver of worsening outcomes in dialysis patients with heart failure, and inadequate decongestion increases mortality risk, according to the American Journal of Kidney Diseases 1, 2.
• Distinguishing between true volume overload versus low cardiac output states is crucial, as management differs fundamentally—if uncertainty exists, right heart catheterization should be performed to guide therapy, as recommended by Circulation 3, 1.

Dialysis Prescription Optimization

• The American Journal of Kidney Diseases suggests adjusting ultrafiltration rate to achieve euvolemia gradually, avoiding ultrafiltration rates exceeding 13 mL/kg/hour, as higher rates associate with intradialytic hypotension, organ ischemia, and cardiovascular events 1, 2.
• The European Journal of Heart Failure recommends using cooler dialysate temperature (35-36°C) to improve hemodynamic stability and reduce intradialytic hypotension risk 4.
• Adjusting dialysate sodium and potassium concentrations is crucial to minimize electrolyte fluctuations that trigger arrhythmias, particularly in the 4-5 hours post-dialysis, as recommended by the European Journal of Heart Failure and Praxis Medical Insights 4.

Guideline-Directed Medical Therapy Management

• The American Journal of Kidney Diseases recommends continuing ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists (MRAs) in dialysis patients with heart failure, as these medications provide mortality benefit regardless of kidney function 1, 2.
• The European Journal of Heart Failure suggests monitoring potassium closely but continuing MRA therapy—if potassium exceeds 6.0 mmol/L, temporarily holding MRA and adjusting dialysate potassium rather than permanently discontinuing 5, 6.
• Circulation recommends continuing beta-blockers and optimizing them after volume status stabilizes, as they reduce sudden cardiac death risk in dialysis patients 3, 4.

Addressing Reversible Causes

• The European Journal of Heart Failure recommends discontinuing nephrotoxic agents, such as NSAIDs, aminoglycosides, and contrast agents, which may precipitate acute-on-chronic kidney injury 5, 6.
• Circulation suggests evaluating for active ischemia, arrhythmias, or valvular disease that may be precipitating heart failure decompensation 3, 8.

Monitoring Strategy

• The American Journal of Kidney Diseases recommends monitoring volume status clinically at each dialysis session, adjusting ultrafiltration goals based on symptoms, weight trends, and blood pressure response 1.
• The European Journal of Heart Failure suggests checking electrolytes (particularly potassium and magnesium) weekly during acute decompensation, then monthly once stable 5, 6, 4.

Critical Pitfalls to Avoid

• The American Journal of Kidney Diseases warns against discontinuing ACE inhibitors, ARBs, or MRAs due to rising creatinine in dialysis patients, as these medications improve survival regardless of kidney function 1, 2.
• Circulation recommends avoiding aggressive ultrafiltration (>13 mL/kg/hour), which causes intradialytic hypotension, myocardial stunning, gut ischemia, and paradoxically worsens outcomes 1, 3.
• The European Journal of Heart Failure advises against combining ACE inhibitor + ARB + MRA, as this dramatically increases hyperkalemia risk without additional benefit 5, 6.